Eli Lilly and Company (NYSE:LLY) is one of the best growth stocks to buy for the next 2 years. On August 27, Eli Lilly and Company announced that its drug, Verzenio (abemaciclib), combined with ...

Many HER2-targeting therapies require pre-treatment HER2 testing. HER2 biomarker tests are used to determine whether the ...

HR biomarker testing is primarily done via immunohistochemistry (IHC) and detects the presence of estrogen receptors (ERs) ...

Despite its Phase III win, analysts state that trastuzumab pamirtecan will likely play a 'me too' role in the US and EU ...

HERTHENA-Breast04 Trial of Patritumab Deruxtecan Initiated in Patients with Metastatic HR+/HER2- Breast Cancer ...

Patients with early-stage, node-negative, hormone receptor (HR)-positive, HER2- negative breast cancer who have a high risk of recurrence based on the OncotypeDX genomic test had better outcomes ...

TROP2 is a protein broadly expressed in HR positive, HER2 negative breast cancer and is associated with increased tumor progression and poor survival. 8,9 About Datopotamab Deruxtecan (Dato-DXd) ...

The FDA has approved Vyloy for patients with HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma with CLDN18.2-positive tumors.

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today it has received CE IVDR approval for two label expansions for its VENTANA® ...

Early Stages Treatment of early-stage HER2-positive breast cancer is similar to that of HER2-negative breast cancer, but it usually also includes a HER2-targeted drug such as Herceptin.